VivoSim Labs (NASDAQ:VIVS) Shares Up 2.6% – Here’s Why

Shares of VivoSim Labs, Inc. (NASDAQ:VIVS) shot up 2.6% during trading on Friday . The company traded as high as $2.05 and last traded at $1.98. 14,438 shares traded hands during trading, a decline of 65% from the average session volume of 41,178 shares. The stock had previously closed at $1.93.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

VivoSim Labs Stock Up 2.6%

The company has a 50-day moving average of $2.30 and a 200-day moving average of $2.28. The company has a market cap of $5.17 million, a PE ratio of -0.45 and a beta of 1.27.

VivoSim Labs (NASDAQ:VIVS) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.98) EPS for the quarter. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%. The company had revenue of $0.03 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP purchased a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs as of its most recent filing with the Securities and Exchange Commission (SEC). 8.23% of the stock is currently owned by hedge funds and other institutional investors.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.